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Abstract 
We have optimized a formulation of a prodrug of dexamethasone (DXM), dexamethasone 
palmitate (DXP) for pulmonary delivery as a dry powder. Formulations were prepared by spray 
drying DXP with 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and Hyaluronic Acid 
(HA) as excipients. Large porous particles around 13 m were produced with a tap density of 
0.05g/cm3 and a Fine particle fraction around 40%. The palmitate moiety favors DXP insertion 
into DPPC bilayers therefore limiting its in vitro release as shown by differential scanning 
calorimetry. After administering DXP powder intratracheally to rats by insufflation, 
bronchoalveolar lavage fluid (BALF) and blood samples were collected up to 24h and DXP and 
DXM concentrations were determined by HPLC analysis after extraction. PK parameters were 
evaluated according to a non-compartmental model. We observe that DXP remains for up to 
6h in the epithelial lining fluid (ELF) of the lungs at very high concentration. In addition, DXP 
concentration decreases according to two characteristic times. Consequently, DXM can be 
detected at rather important concentration in ELF up to 24h. The passage of DXP from the 
lungs to the bloodstream is very poor whereas DXM seems to be absorbed in the blood more 
easily. These results suggest that once administered DXP undergoes two different processes: 
hydrolysis into DXM due to the presence of esterases in the lungs and distribution in the lung 
tissue. This formulation appears promising to reduce systemic exposure and prolong the 
effect of the drug locally. 
 
Keywords: Dexamethasone palmitate; Dexamethasone; large porous particles; spray drying; 
lung delivery; pharmacokinetics. 
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1. Introduction 
Asthma is a chronic inflammatory disorder of the airways, usually associated with airway 
hyper-responsiveness and variable airflow obstruction, that can be reversed either 
spontaneously or under treatment (Asthma, 2014). Allergen sensitization is an important risk 
factor for asthma (Bateman et al., 2008) and for the past 40 years, the prevalence of asthma 
has increased in all countries in parallel with that of allergy. It is estimated that as many as 
300 million people of all ages in the world suffer from asthma (Asthma, 2014).  Anti-asthmatic 
treatments can be administered via different routes of administration such as parenteral or 
oral (prednisone) but the pulmonary route is often preferred, as it allows delivering the 
medication right to the site of action where it is needed. Anti-asthmatic treatments vary 
depending on the extent of the disease but for quick relief they mostly consist in a 
combination of beta2 adrenergic agonists and corticosteroids. Beta2 adrenergic agonists such 
as albuterol, levalbuterol, metaproterenol or terbutaline are used as bronchodilators helping 
to relax airway muscles within 5 minutes (Spina, 2014). They lead to an increase of the airflow, 
facilitating patient breathing. Beta2 adrenergic agonists help relieving asthma symptoms for 3 
to 6 hours. Corticosteroids such as beclomethasone propionate, fluticasone furoate or 
propionate, budesonide, ciclesonide, or flunisolide are used for their anti-inflammatory 
effects and required several administrations per day. Inhaled corticosteroids are effective in 
the treatment of asthma because of their ability to interfere with multiple inflammatory 
processes involved in the asthmatic pathology (Allen et al., 2003; Barnes and Pedersen, 1993; 
Crim et al., 2001). Inhalation offers advantages for the treatment of asthma using 
corticosteroids as compared with the systemic route. It helps, with efficiency and optimal 
tolerance; to locally treat a condition that requires the use of high doses of active product by 
systemic route. The inhaled corticosteroids allow a rapid onset of action and induce fewer 
side effects than does administration by other routes (Beck-Broichsitter et al., 2009; Boisson 
et al., 2014). However, these benefits are often associated with limited lung deposition and 
short duration of action because of respiratory protection mechanisms (Hanania et al., 1995). 
Thus, the ideal inhaled corticosteroid should have: long residence time in the lung; intrinsic 
activity; low oral bioavailability and high systemic clearance resulting in negligible systemic 
side effects. However, most currently marketed inhaled corticosteroids still require several 
daily administrations (Burgt et al., 2000; Czock et al., 2005; Hübner et al., 2005). To modify 
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corticoids residence time in the lungs, an appropriate formulation can be developed  to 
deliver these molecules. 
Lung delivery can be achieved by nebulization of drug solutions (Rodrigo, 2015) or 
suspensions of nanoparticles (Sahib et al., 2011), or using either metered dose inhalers(Berger 
et al., 2014) or dry powders for inhalation (Chawes et al., 2014). Current formulation 
approaches of corticosteroid dry powders consist in micronizing the active pharmaceutical 
ingredient and blend it with lactose as a carrier, which characteristics can be optimized 
(Buttini et al., 2008; Donovan and Smyth, 2010; Hoppentocht et al., 2014). Alternatively, large 
porous particles (LPPs), characterized by geometric sizes greater than 4-5 µm and mass 
densities lower than 0.4 g/cm3, have been introduced for both local and systemic applications 
by the pulmonary route to the lungs (Cruz et al., 2011; Edwards and Dunbar, 2002; Edwards et 
al., 1997; Gervelas et al., 2007; Pham et al., 2015). A major advantage of LPPs relative to 
conventional inhaled therapeutic aerosol particles is their aerosolization efficiency (Dunbar et 
al., 1998; Edwards and Dunbar, 2002). This allows the supply of large drug masses using a 
simple inhalation device (Edwards, 2002). These characteristics suggest that inhalation of LPPs 
may be beneficial in the treatment of asthma by delivering the corticosteroids directly to the 
primary site of inflammation to achieve therapeutic local drug concentrations with low 
systemic exposure. 
To favor prolonged efficacy of the corticosteroid it appeared interesting to combine LPPs with 
a corticosteroid prodrug. We have chosen to use a prodrug of dexamethasone since this 
corticosteroid is often used a reference to evaluate the efficacy of other molecules (Kelly, 
2009). Dexamethasone palmitate is of particular interest since its aliphatic chain may help 
modulating its release from lipid-based LPPs. As excipients,dipalmitoyl-snglycero-3-
phosphatidylcholine (DPPC) and hyaluronic acid (HA) have been chosen due to their 
biocompatibility, biodegradability and ability to yield porous particles (Gomez-Gaete et al., 
2008). DXP encapsulation into DPPC-HA microparticles was optimized by spray drying, varying 
DXP concentration with respect to the lipid content. Physico-chemical characterization of the 
powders will be presented as well as aerosolization efficacy using a multistage liquid impiger 
and drug release in sink conditions. Once the formulation optimized, pharmacokinetics of DXP 
and its active metablite dexamthasone (DXM) were determined in plasma and epithelial lung 
fluid after intratracheal administration of the DXP powder by insufflation.  
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The aim of the work is therefore to optimize the formulation of DXP by spray-drying into large 
porous particles and to evaluate their pharmacokinetics and lung distribution in vivo in rats. 
We expect the delivery of a lipidic corticosteroid prodrug will allow to prolong drug residence 
in the lungs.  
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2. Materials and methods 
  
2.1 Materials  
Dexamethasone palmitate (DXP) was provided by Interchim (France), Dexamethasone (DXM) 
and Dexamethasone acetate (DXA) were provided by ChemosGmbH (Germany) , Testosterone 
decanoate (TC) was provided by Sigma–Aldrich (France), 1,2-dipalmitoyl-sn-glycero-3-
phosphatidylcholine (DPPC) by Corden Pharma (Switzerland) and hyaluronic acid, sodium salt 
95% (HA) (MW = 1 000 kDa) by Acros Organics. Acetonitrile was of high-performance liquid 
chromatography (HPLC) grade. All chemicals used were of analytical grade. Organic solvents 
were provided by Carlo Erba (Italy) and were of analytical grade when not specified. Water 
was purified using a RIOS/MilliQ system from Millipore (France). 
 
2.2 Microparticles preparation  
DXP-loaded microparticles were prepared by spray drying using a mini spray-dryer BÜCHI B-
290 (France) equipped with a 0.7 mm diameter two-fluid nozzle, which operates in a co-
current mode according to conditions detailed in Table 1. An aqueous solution of HA was 
prepared by dissolving 200 mg of HA into 150 ml of water upon magnetic stirring at room 
temperature. An ethanolic solution was prepared by dissolving DPPC and DXP into 350 ml of 
ethanol absolute to obtain a final amount of 800mg of lipophilic compounds. The weight 
percent of DXP was varied between 0 and 15%. Ethanolic and aqueous solutions were then 
mixed at a ratio of 70/30 (v/v) prior to spray-drying and the mixture maintained under 
moderate stirring while fed into the spray-dryer. The yield was calculated as a percentage of 
the mass of the powder collected divided by the initial mass of solids in the solution prior to 
spray-drying. 
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Table 1. Operational conditions used for spray-drying. 
Feed flow rate (mL/min)  17 
Inlet temperature (ºC)  150 ± 2 
Outlet temperature (ºC)  55 ± 4 
Aspiration setting (%)  100  (35m3/h) 
Air-flow rate (L/h)  414 
 
2.3. Particle size distribution 
Powders size distributions were measured by light diffraction using a Mastersizer 2000 
equipped with a Scirocco dry disperser (Malvern Instruments, France) at a dispersing pressure 
of 3 bars. The refractive index used was 1.5. Data obtained were expressed in terms of the 
particle diameter at 10%, 50% and 90% of the volume distribution (D10, D50 and D90 
respectively). The span of the volume distribution, a measure of the width of the distribution 
relative to the median diameter was calculated according to Eq 1. A large span is indicative of 
a more heterogeneous size distribution. Values presented are the average of at least 3 
determinations. 
50
1090
D
DD
Span

   (Eq. 1) 
 
2.4. Tap density and aerodynamic diameter 
Powder tap density (ρ) was determined using a tapping apparatus (Pharma test PT-TD1). 
Accurately weighed powder samples were filled into a 5 ml graduated cylinder and the height 
measured following 1000 taps which allowed the density to plateau (Pharmacopoeia, 2013). 
Assuming an efficient packing, the tap density of monodisperse spheres is approximately a 
21% underestimate of the true particle density due to the void spaces between particles. 
Although polydispersity may reduce the void volume between particles, this is probably 
counterbalanced by an imperfect packing (Vanbever et al., 1999). Measurements were 
performed in duplicate. 
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2.5. Scanning electron microscopy 
Scanning electron microscopy (SEM) was performed using a LEO1530 microscope (LEO 
Electron Microscopy Inc., Thornwood, USA) operating between 1 and 3 kV with a filament 
current of about 0.5 mA. Powder samples were deposited on carbon conductive double-sided 
tape (Euromedex, France) and were coated with a palladium–platinum layer of about 4 nm 
using a Cressington sputter-coater 208HR with a rotary planetary-tilt stage, equipped with a 
MTM-20 thickness controller. 
 
2.6. Differential scanning calorimetry (DSC) 
The DSC analysis was performed on hydrated samples (0 to 15% DXP) on a differential 
scanning calorimeter (DSC7, Perkin-Elmer, USA). About 10 mg of powder was hydrated with 
100 µl of water 12 h before experiments. Then about 15 mg of hydrated samples were loaded 
into 40 µl aluminum pans and analyzed. The DSC runs were conducted from 20 to 80 °C at a 
rate of 5 °C/min. Calibration was achieved using Indium (Tonset = 156.60 °C) as well as n-decane 
(Tonset = - 29.66 °C). Experiments were performed at least in duplicate. Enthalpies were 
normalized with respect to DPPC weight in the sample. 
 
2.7. Aerosolization characterization 
The aerodynamic particle size distribution was determined using a Multi-Stage Liquid 
Impinger (MSLI). A dry powder inhalation device (Aerolizer®, Novartis, Switzerland) was filled 
with a size 3 capsule made of hydroxypropylmethyl cellulose (HPMC, LGA France) containing 
the powder. The test was carried out at 60 L/min for 4 s with a ratio of pressure P3/P2 < 0.5. 
Five capsules loaded with an average of 10 mg powder were taken for each test. Drug 
deposition in the device, the piece mimicking the throat, the four stages and the filter was 
determined by HPLC analysis. For accuracy, each test was repeated three times. The particles 
with aerodynamic diameters smaller than 5 µm and 3.1 µm were determined by interpolation 
from the cumulative amount of respective stages and considered as the fine particle fraction 
(FPF) (%) and as the alveolar particle fraction (AF) (%) expressed as a percentage of the 
loaded/nominal dose (Hinds, 1999; Pharmacopoeia, 2013). 
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2.8 DXP release from microparticles 
Drug release from microparticles prepared with 5% DXP was carried out  the following way: 25 
mg of microparticles were accurately weighted, resuspended in 25 mL of PBS (corresponding 
to a final  DXP concentration of 50 µg/mL) and the preparation was protected from light and 
placed at 37 °C under magnetic stirring. At each time point, the suspension was vortexed and 
1 mL was collected. 100 µL of the vortexed sample was diluted to the tenth (1/10) in 
acetonitrile, in order to determine total DXP concentration. The remaining 900 µL were 
centrifuged (13.000 rpm, 15 min) (Mini Spin Eppendorf centrifuge) and 100 µL of the 
supernatant were diluted to the tenth in acetonitrile, to determine DXP concentration in the 
supernatant. After filtration (0.45 μm PVDF filter), samples were stored at 4°C until analysis by 
HPLC as described below. Experiments were performed in duplicate. 
 
2.9 Pharmacokinetics and bronchoalveolar distribution study 
Sprague Dawley male rats with average weight of 300g were obtained from Envigo (Gannat, 
France). All animal experiments were carried out in accordance with the Principles of 
Laboratory Animal Care as adopted and propagated by the EU guidelines for Animal 
Experiments (86/609/EEC and 2010/63/EU) and Legislation in force in France (Decree No. 
2013-118 of February 1, 2013). They were housed 4 per cage while on study in accordance to 
EEC guidelines. The light/dark cycle was 12 h/12 h. The temperature in the animal room was 
ambient room temperature of approximately 25 °C and the ambient humidity was in the 
range of approximately 35–60%. Animals were allowed access to food and water ad libitum 
throughout the duration of the study. 
Rats were anesthetized with an intraperitoneal injection of a mixture of ketamine (100 mg.kg-
1) and xylazine (10 mg.kg-1) and then intratracheally administered with 3mg of DXP powder 
corresponding to 150g of DXP using a Microsprayer (PennCentury, Philadelphia, PA) (Kohno 
et al., 2010; Neuhaus et al., 2011; Wijagkanalan et al., 2008). Powder was delivered through 
the insufflation device by rapidly pushing a 2 cm3 bolus of air through the device. After 
administration, rats were supported vertically for 1 min. Blood and bronchoalveolar fluid were 
collected at t=30min, 1h, 2h, 3h, 4h, 6h, 18h and 24h after administration.  For each rat, blood 
was taken at 3 different time points via the jugular vein (Khoder et al., 2010; Nave et al., 
2010). At least 3 different rats were used for each time point. Before taking the blood, the rats 
were anesthetized by isoflurane inhalation. Blood samples (1mL) were collected in citrated 
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tubes and immediately separated at 4000 rpm during 5 min at room temperature (20°C) using 
a microcentrifuge (Minispin Eppendorf). Plasma was aspirated and frozen at -80°C until 
further analysis. Bronchalveolar lavage fluid (BALF) was collected by lavaging lungs three times 
with 1mL of PBS per intratracheal lavage. The lungs were massaged and the fluid withdrawn 
immediately and collected in centrifuge tube kept on ice. The rats were euthanized by cardiac 
puncture under deep isoflurane anesthesia before BALF collection. The trachea was 
cannulated using an 18 gauge needle adaptor for subsequent injection and retrieval of BALF. 
Then BALF collected was frozen at -80°C until further analysis. PK of DXP and DXM in plasma 
and ELF were evaluated according to a non compartmental model. PK parameters were 
calculated using GraphPad Prism (Version 5 software for windows, Inc.). The AUC was 
calculated from time zero to the last blood collection time (24h). 
 
 
2.10 Extraction of DXP or DXM from plasma and BALF. 
Extraction of DXP and DXM from either plasma or BALF was performed as follows (Alhareth et 
al., 2012). In an amber glass tube to protect DXP and DXM from light (REF), 100µL of plasma or 
BALF and 100µL of internal standards (testosterone decanoate (TD) for DXP and 
dexamethasone acetate (DXA) for DXM, both at 4g/mL in acetonitrile were added and 
vortexed during 30 seconds. Then 3mL of a chloroform:methanol mixture (9:1, v:v) were 
added in the tube. Sample was vortexed during 3 min to obtain protein precipitation and then 
was centrifuged during 10 min at 10,000 rpm using a min centrifuge (minispin eppendorf, 
France). The organic phase in the bottom was transferred into a clean amber vial and 
evaporated to dryness under a stream of nitrogen at 30°C. The residue was then reconstituted 
into 100µL of acetonitrile and vortexed prior to analysis using HPLC conditions described 
below.  
  
2.11 HPLC method 
Quantification of DXM or DXP concentration in microparticles, in PBS (release), in plasma and 
in BALF was performed by HPLC. A WaterTM 2707 autosampler chromatographic system was 
employed equipped with a WatersTM 1525 binary HPLC pump, a WatersTM 2998 photodiode 
array detector, and a WatersTM Breeze software. The analysis was performed at 240 nm using 
a SymmetryShieldTM RP18 column (5 µm, 250×4.6 mm; Waters, Saint-Quentin-en-Yvelines, 
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France). Column temperature was maintained at 40 °C using a column Heater (Model 1500, 
Waters Corporation). The mobile phase was composed by a mixture of acetonitrile and milliQ 
water: 85/15 v/v for DXP and 35/65 v/v for DXM. The mobile phase flow rate was 1.2mL/min, 
the injection volume was 50L and the run time was 30min. Retention times were 24min and 
9min for DXP and DXM, respectively, 21min for TD and 26min for DXA. Each sample was 
analyzed twice, once with DXP quantification method, second with DXM quantification 
method. For quantification from in vitro samples, the developed method showed good 
linearity between 0.5 and 250 µg/mL (y = 50896x – 1239; r2 = 0.998) for DXP and 0.3 and 260 
µg/mL (y = 43920x + 9731; r2 = 0.9995) for DXM. For quantification from in vivo samples, limits 
of detection and quantifications were determined. 
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3 Results and discussion 
3.1- Powder characteristics 
DXP microparticles were obtained by spray-drying by varying the DXP content up to 15% 
(w/w), We obtained white and fluffy powders. Polydisperse aggregated spherical 
microparticles exhibiting some roughness were observed by SEM, with a tendency to 
aggregation as DXP content increased (Figure 1). 
 
Figure 1: SEM images of typical microparticles obtained by spray drying. Image A corresponds 
to DPPC-HA microparticles exempt of DXP, Images B to D correspond to 5, 10 and 15% DXP 
(w/w), respectively. 
 
Laser diffraction granulometry confirmed SEM observations with a median volume geometric 
diameter D50 between 12.3 and 13.7 µm, and a span between 2 and 3, with no obvious trend 
as DXP content increases (Figure 2A and 2B). The tap density varies between 0.053 and 
0.066g/cm3, independently of DXP content (Figure 2C). The low tap density indicates 
microparticles present some porosity as observed previously with DXM using the same 
excipients (Gomez-Gaete et al., 2008).  The powder yield however showed a decrease from 
34% to 26% as DXP concentration increased from 0 to 15%. This yield decrease is associated 
with an increase in powder cohesion. This result is in agreement with previous ones obtained 
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when incorporating dexamethasone in a similar formulation (Gomez-Gaete et al., 2008): the 
higher the drug content, the more cohesive the powder. 
 
 
Fig 2 : Microparticles characteristics in terms of median volume geometric diameter (D50, A), 
span (B), tap density (C) and yield (D) as a function of the weight percent of DXP in the 
formulation. Results are presented as mean±SD (n=3). 
The aerodynamic behavior of the powder was then evaluated in terms of emitted fraction, 
fine particle fraction and alveolar fraction. The emitted fraction was 98±2% independently of 
the formulation. Contrary to microparticle median size, span or tap density, a clear trend can 
be observed for both the FPF and the AF that decrease as DXP weight percent increases 
(Figure 3). The FPF and AF varies from 40±7% to 14±1% and from 30±6% to 7±1%, 
respectively. This decrease is most probably related to powder cohesion as described above. 
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Fig 3: Fine particle fractions (FPF) and Alveolar fractions (AF) of DXP microparticles 
determined using an MSLI as a function of DXP weight percent in the formulation. Values are 
presented as the mean± SD (n=3). 
Given these results, we decided to focus on microparticles formulated with 5% DXP which 
lead to the highest FPF and AF with a good yield.   
 
3.2. In vitro release of DXP 
DXP release from 5% DXP microparticles was followed during several days. About 2% of DXP 
was immediately released after vortexing. This burst effect corresponds to a concentration of 
1µg/mL. Then a gradual and rather slow release was observed for 21 days from 2% to about 
5% (Figure 4). It should be noted that no dexamethasone was detected during this 
experiment. Although the release conditions are very different from what would happen in 
vivo, results indicate a sustained release from the microparticles. In vivo, we expect that 
esterases and lipases would accelerate considerably the release, as observed by others (Lu et 
al., 2009). In addition, one should note that the solubility of DXP in PBS was not measurable. 
The fact that we detect DXP in our release experiment might be favoured by the presence of 
DPPC. Although this specific phospholipid is very hydrophobic, it possesses a critical micellar 
concentration of 0.46nM at 20°C (Smith and Tanford, 1972). The very few micelles probably 
help solubilising DXP. 
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Fig 4: In vitro DXP release from 5% DXP microparticles in PBS at 37°C. 
 
3.3 Differential scanning calorimetry (DSC) 
To better understand DXP release, DSC was performed on hydrated samples to assess the 
possible interactions between DPPC and DXP (0% to 15%). For hydrated microparticles made 
without DXP, the DSC thermogram exhibit a very flat pretransition of DPPC due to the 
interaction with HA and the typical main phase transition of DPPC at Tonset= 42.3°C with an 
enthalpy ΔH=45.8J/g (Figure 5). This result is in agreement with those obtained for similar 
microparticles (Gomez-Gaete et al., 2008). When hydrated, lipid bilayers swell forming typical 
liquid crystalline phases of DPPC (Gomez-Gaete et al., 2008). As DXP content increases, the 
pretransition does not appear anymore. The onset temperature of the main DPPC transition 
shifts down to 39°C and the enthalpy of DPPC decreases (Figure 5). At 15% DXP, one can also 
observe the appearance of a thermal event with a Tonset of 55.7ºC. We do believe this thermal 
event corresponds to a phase transition of DXP, although nothing can be found in the 
literature.  Indeed when DSC experiments were conducted with higher DXP content, the peak 
became more important (data not shown). The combination of the decrease of the onset 
temperature of DPPC and of its enthalpy (Fig 6) is the signature of the insertion of DXP within 
the DPPC bilayer as observed for cholesterol (Kessel et al., 2001). This insertion is rather 
logical since DXP possesses an aliphatic chain of 16 carbons, the exact same length as DPPC 
aliphatic chains. DXP insertion within bilayers further explains the slow release observed upon 
incubation. 
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Fig 5: DSC thermograms obtained from hydrated powders upon heating at 5°C/min with 
different concentrations of DXP (0 to 15%). The arrow indicates the position of the DPPC main 
transition around 40°C, whereas the star indicates what we believe corresponds to a 
transition associated to DXP (Panel A). Variation of the onset temperature (B) and of the 
enthalpy (C) of DPPC main transition as a function of DXP concentration in the powder. Values 
are presented as mean±SD (n=3). Error bars are smaller than the size of the symbols. 
  
A
B
C
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3.4 In vivo experiments 
The extraction method for biological samples was satisfactory with extraction yields for DXP of 
84 ± 2% for extraction from BALF, and 66 ± 7% for extraction from plasma, as well as for DXM 
with 87 ± 4% extraction from BALF and 83 ± 7% extraction from plasma. Limits of detection 
(LOD) and quantification (LOQ) for each molecule are presented in Table 2. The results of DXP 
and DXM obtained in BALF were converted to epithelial lining fluid (ELF) concentrations 
according to the theoretical volume of ELF reported in the literature (30 L/kg) and to the 
volume of PBS used for bronchoalveolar lavage (1mL). Thus, for a rat of 300g, the dilution 
factor determined by calculation was 333 (Gontijo et al., 2014).  
 
Table 2: Limits of detection and quantification of the different molecules after extraction from 
plasma or BALF.  
Parameters Plasma BALF ELF 
DXM 
LOQ (µg/mL) 0.133 0.1 33 
LOD (µg/mL) 0.04 0.03 10 
DXP 
LOQ (µg/mL) 0.17 0.1 33 
LOD (µg/mL) 0.06 0.03 10 
 
All PK parameters are presented in Table 3 for both DXP and DXM. The results of DXP and 
DXM concentrations obtained in ELF are presented in figure 6 as semi-log plots. The maximal 
concentration of DXP in the ELF is obtained 30 min after administration with a value CDXP-ELF-
max= 10794 µg/mL. It corresponds to  about 65% of the theoretical initial concentration given 
the administered dose. Then the DXP concentration decreases and can be described by three 
different phases. The first phase occurs between 30min and 3h corresponding to a slow 
decrease from 10794 µg/mL (65% of initial theoretical concentration) to 5657µg/mL (34% of 
initial theoretical concentration). This first phase can be fitted by a single exponential 
decrease y= yAexp(-k1/t) with k1= 0.247 h
-1 and a characteristic half-time t1/2A=
   
  
= 2.8±0.4 h. 
The second phase corresponds to a faster decrease between 3h and 6h from 5657 µg/mL to 
204 µg/mL, which corresponds to 1.2% of the initial theoretical concentration. This second 
decrease can be fitted by a single exponential decrease y= yBexp(-k2/t) with k2=1.09h
-1 and a 
characteristic half-time t1/2B=
   
  
= 0.63±0.01 h.  The last phase suggests a slow elimination of 
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DXP from ELF although it cannot be modeled since the last two concentrations at 18h and 24h 
were below the LOQ of DXP in ELF. For DXM in ELF, one can observe a rapid decrease of 
concentration between 30 min and 4h, then the concentration remains stable but very low 
below the LOQ. The decrease can be fitted by a single exponential decrease y= yAexp(-k1/t) 
with k1=0.743h
-1 and a characteristic half-time t1/2=
   
  
= 0.93±0.20 h. The area under the curve 
(AUC) of DXP in ELF was 26 703 µg.h/mL whereas for DXM the exposure was much lower with 
an AUC around 674 µg.h/mL (Table 3). 
 
 
 
 
Figure 6: Concentration of DXP (top) and DXM (bottom) in ELF after intratracheal insufflation 
of 3mg of DXP microparticles (DXP dose=150 g). LOQs are represented as dashed curves and 
LOD as full curves. The LOD is 10 g/mL. Data are presented as mean±SEM (Standard error of 
the mean), n=3. 
 
The concentrations found in the plasma were very low for DXP with values between the LOQ 
and the LOD (Figure 7). The systemic exposure to DXP in the plasma therefore cannot be 
determined. For DXM, the concentrations found in plasma are low but above the LOQ and 
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seem to follow a two-step decrease (Figure 7). The first decrease takes place between 30min 
and 4h and can be fitted by a single exponential decrease y= yAexp(-k1/t) with k1= 0.207 h
-1 
and a characteristic half-time t1/2A=
   
  
= 3.34±0.33 h. The second phase corresponds to a 
slower decrease between 4h and 24h and can be fitted by a single exponential decrease y= 
yBexp(-k2/t) with k2=0.0182h
-1 and a characteristic half-time t1/2B=
   
  
= 38h±10h. The plasmatic 
exposure to DXM can be quantified by calculating the AUC and one finds 4.89 µg.h/mL (Table 
3). 
 
 
Figure 7: Concentration of DXP (top) and DXM (bottom) in plasma after intratracheal 
insufflation of 3mg of DXP microparticles (DXP dose=150 g). LOQs are represented as dashed 
curves and LOD as full curves. The LOD of DXM in plasma was not presented as all values were 
above the LOQ. Data are presented as mean±SEM (Standard error of the mean), n=3. 
 
The ELF/plasma AUC ratio is around 138 for DXM and could not be calculated for DXP. This 
suggests a very pronounced local delivery and a rather low passage of molecules from the 
lungs to the blood stream. Experimental concentrations could be explained by three main 
phenomena as described in Figure 8: powder solubilization, DXP hydrolysis into DXM, 
DXP/DXM distribution in lung tissue and DXP/DXM passage in the blood stream. Indeed, the 
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first part of the DXP curve in ELF may correspond to the solubilization of particles to release 
DXP molecules along with hydrolysis of DXP into DXM occuring due to the presence of 
esterases in the ELF (Basu et al., 1988; Deimling et al., 1983). The fast decrease of DXP 
concentration in ELF probably corresponds to DXP distribution in lung tissue. This distribution 
is favored by DXP lipophilicity. DXP lipophilicity also explains the very low DXP concentration 
detected in the bloodstream (Derendorf et al., 1998; Edsbäcker and Johansson, 2006; 
Georgitis, 1999). One can notice that DXM is cleared faster from ELF (t1/2A of about 1h) than 
from the plasma (t1/2A of about 3h) due to the route of administration and the physico-
chemical properties of the molecule. DXM is absorbed in the blood more efficiently than DXP 
since it is less lipophilic. The second decrease of DXM concentration observed in the plasma 
with a very long half-life of 38h most probably corresponds to the elimination phase of the 
drug. One can hypothesize that the lung tissue contains a very high content of DXP that is 
slowly converted into DXM which in turn is absorbed in the bloodstream (Johnson, 1996). 
 
Table 3: PK parameters (mean  SEM) after intratracheal insufflations of 3mg of DXP powder 
corresponding to a dose of 150 g of DXP (93 g of DXM). 
Parameters ELF Plasma 
DXM 
Cmax (µg/mL) 191 0.37 
tmax (h) 0.5 0.5 
AUC (µg.h/mL) 674 4.89 
AUC/Dose (h/mL) 7.22 0.053 
t1/2A (h) 0.93±0.20 3.34±0.3 
t1/2B (h) NA 38±10 
AUCELF/AUCPlasma  138 
DXP 
Cmax (µg/mL) 10 794 NA 
tmax (h) 0.5 NA 
t1/2A (h) 2.8±0.4 NA 
t1/2B (h) 0.63±0.01 NA 
AUC (g.h/mL) 26 703 NA 
AUC/Dose (h/mL) 178 NA 
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Cmax, maximal concentration in ELF and in plasma; tmax, time of maximal concentration in ELF 
and in plasma ; AUC, area under the curve of ELF and plasma concentrations ; t1/2, terminal 
half-life in ELF and in plasma. 
 
 
 
Figure 8: Schematic description the different phenomena occuring after DXP microparticles 
are delivered to the lungs. 
 
Our analytical conditions were not sufficient to quantify properly DXM in ELF but this 
molecule could be detected up to 24h suggesting a prolonged local effect.  DXM and DXP were 
not dosed in the lung tissue since it is difficult to fully exsanguinate the animal and therefore 
to separate what accounts for tissue from what accounts for remaining blood. Although 
inhaled corticosteroids are prescribed daily, the literature is very scarce about comparison 
between ELF and plasma concentrations after lung administration on animal models. An 
article by Mo et al. (Mo et al., 2014) presents the pharmacokinetic study of prednisolone 
administered by intratracheal instillation at the dose of 1mg/kg to guinea pigs of about 300g. 
They compared ethanol/water 3/1 (v/v) solutions of prednisolone and  L-carnitine esters of 
prednisolone. The resulting AUC of prednisolone after prednisolone succinate-L-carnitine 
administration was around 100 µg.h/L=0.1 µg.h/mL. If one divides this value by the dose of 
prednisolone the AUCPRED/dose= 0.0033 h/mL, whereas we find 0.053 h/mL for DXM in 
plasma, signature of a higher systemic exposure for rather similar doses (1mg/kg equivalent 
prednisolone and 0.3mg/kg equivalent DXM). Concentrations in ELF could not be compared 
since these authors measured drug in tissue and not in the lavage fluid. However prednisolone 
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succinate-L-carnitine could be quantified in the lung tissue up to 6h after administration. 
These results are in agreement with what we have obtained. Since Mo et al. have shown an 
anti-asthmatic efficacy, our microparticles of DXP might hold great potential to prevent 
inflammation in the lungs. 
4. Conclusion 
We have optimized a formulation of a prodrug of dexamethasone, dexamethasone palmitate 
for pulmonary delivery as a dry powder. In vitro drug release is rather slow with less than 5% 
of DXP in the supernatant after 21 days, and arises from DXP insertion within the DPPC 
bilayers once powders were hydrated. Although a thorough model of what is happening after 
DXP microparticle lung administration cannot be proposed, one can notice that the prodrug 
(DXP) remains for up to 6h in the ELF at very high concentration, that the drug itself (DXM) can 
be detected at rather important concentration in ELF up to 24h. The passage of DXP from the 
lungs to the bloodstream is very poor whereas DXM seems to be absorbed in the blood more 
easily. Overall however the systemic exposure seems low compared to the lung exposure 
which suggests limited side effects. Therapeutic efficacy of this formulation remains to be 
evaluated in the future by using asthmatic animal models. The strategy of using a lipophilic 
prodrug could be extended to other molecules to promote long residence time in the lungs 
while reducing drug systemic exposure. 
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